Noninfective drug-related pneumonitis (DRP) is a well-known adverse effect of several drugs: clinical manifestations have mostly an acute/subacute onset and vary from mild to life-threatening. Several DRP cases have been described in patients receiving anti-tumor necrosis factor α, rituximab, and tocilizumab.1,2 To date, only 4 reports of vedolizumab-related pneumonitis have been presented.3-5.
Pugliese, D., Privitera, G., Schepis, T., Larosa, L., Onali, S., Scaldaferri, F., Gasbarrini, A., Caprioli, F., Armuzzi, A., Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease, <<CLINICAL GASTROENTEROLOGY AND HEPATOLOGY>>, 2021; 20 (6): e1483-e1487. [doi:10.1016/j.cgh.2021.08.041] [http://hdl.handle.net/10807/204153]
Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease
Pugliese, Daniela;Privitera, Giuseppe;Schepis, Tommaso;Larosa, Luigi;Onali, Sebastiano;Scaldaferri, Franco;Gasbarrini, Antonio;Caprioli, Francesca;Armuzzi, Alessandro
2022
Abstract
Noninfective drug-related pneumonitis (DRP) is a well-known adverse effect of several drugs: clinical manifestations have mostly an acute/subacute onset and vary from mild to life-threatening. Several DRP cases have been described in patients receiving anti-tumor necrosis factor α, rituximab, and tocilizumab.1,2 To date, only 4 reports of vedolizumab-related pneumonitis have been presented.3-5.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
